Skip to main content
Defiance International

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

Human research record. Critical care (London, England), 2013.

  • Human
  • 2013

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 23327199. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Human
Scale
A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.
Comparator
None reported
Journal
Critical care (London, England)
Year
2013
PMID
23327199
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

The trial is to evaluate whether Tα1 improves 28-day all-cause mortality rates and immunofunction in patients with severe sepsis.

Study design

We performed a multicenter randomized controlled trial in six tertiary, teaching hospitals in China between May 12, 2008 and Dec 22, 2010.

Participants or experimental system

Eligible patients admitted in ICU with severe sepsis were randomly allocated by a central randomization center to the control group or Tα1 group (1:1 ratio).

Study scale

A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.

Intervention or exposure

In the Tα1 group, patients received subcutaneous injections of 1.6 mg Tα1 (ZADAXIN™, SciClone Pharmaceuticals, Foster City, CA, USA) twice per day for five consecutive days, then once per day for two consecutive days.

Outcomes examined

The primary outcome was death from any cause and was assessed 28 days after enrollment.

Key findings

Greater improvement of mHLA-DR was observed in the Tα1 group on day 3 (mean difference in mHLA-DR changes between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P = 0.037) and day 7 (mean difference in mHLA-DR changes between the two groups was 5.8%, 95% CI 1.0 to 10.5%, P = 0.017) than in the control group.

Not reported in the declared source: Methods. Not published in this record: Comparator.

Limitations and uncertainty

In our study, several factors limit the extent to which the results can be generalized.

Cite

Cite the study

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
Wu J, Zhou L, Liu J et al. Critical care (London, England). 2013. PMID 23327199

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.